• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Exagen Inc.

    12/12/24 5:00:54 PM ET
    $XGN
    Medical Specialities
    Health Care
    Get the next $XGN alert in real time by email
    SC 13G/A 1 eh240566975_13ga3-xgn.htm AMENDMENT NO. 3

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION
    Washington, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934

     

    (Amendment No. 3)* 

     
    Exagen Inc.
    (Name of Issuer)
     
    Common Stock, par value $0.001 per share
    (Title of Class of Securities)
     
    30068X103
    (CUSIP Number)
     
    December 12, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☐ Rule 13d-1(c)
      ☒ Rule 13d-1(d)

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). 

     

      

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 2 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    Hunt Holdings Limited Partnership

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Texas

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    829,280

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    829,280

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    829,280

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.7%

     
    12

    TYPE OF REPORTING PERSON

     

    PN

     

     

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 3 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    HuntVest, LLC

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Nevada

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    829,280

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    829,280

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    829,280

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.7%

     
    12

    TYPE OF REPORTING PERSON

     

    OO

     

     

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 4 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    Hunt Guaranty, Inc.

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    829,280

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    829,280

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    829,280

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.7%

     
    12

    TYPE OF REPORTING PERSON

     

    CO

     

     

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 5 of 9

     

     

    1

    NAME OF REPORTING PERSON

     

    Woody L. Hunt

     
    2

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

    (a)  ☐

    (b)  ☐

    3

    SEC USE ONLY

     

     

     
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

     

    NUMBER OF

    SHARES

    BENEFICIALLY OWNED

    BY EACH REPORTING

    PERSON

    WITH

    5

    SOLE VOTING POWER

     

    829,280

    6

    SHARED VOTING POWER

     

    0

    7

    SOLE DISPOSITIVE POWER

     

    829,280

    8

    SHARED DISPOSITIVE POWER

     

    0

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    829,280

     
    10

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

    ☐
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

    4.7%

     
    12

    TYPE OF REPORTING PERSON

     

    IN

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 6 of 9

     

     

    ITEM 1. (a) Name of Issuer:
         
       

    Exagen Inc. 

         
      (b) Address of Issuer’s Principal Executive Offices:
         
        1261 Liberty Way, Suite C
        Vista, California 92081
         
    ITEM 2. (a) Name of Person Filing:
         
      This statement is being filed on behalf of each of the following persons (each, a “Reporting Person” and collectively, the “Reporting Persons”):
         
        (i)           Hunt Holdings Limited Partnership (“Hunt Holdings LP”);
        (ii)          HuntVest, LLC (“HuntVest”), the general partner of Hunt Holdings LP;
        (iii)         Hunt Guaranty, Inc. (“Hunt Guaranty”), the sole member of HuntVest; and
        (iv)         Woody L. Hunt (“Mr.Hunt”), the majority shareholder of Hunt Guaranty.
         
      (b) Address of Principal Business Office, or if none, Residence:
         
        601 N. Mesa Street, Suite 1900
        El Paso, TX 79901
         
      (c)

    Citizenship:

         
        See row 4 of the cover page of each Reporting Person.
         
      (d)

    Title of Class of Securities:

         
        See cover page.
         
      (e)

    CUSIP Number:

         
        See cover page.
         
    ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §240.13D-1(B) OR 240.13D-2(B) OR (C), CHECK WHETHER THE PERSON FILING IS A:
       
      Not applicable.

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 7 of 9

     

    ITEM 4. OWNERSHIP
           
      (a)

    Amount beneficially owned:

           
       

    See row 9 of the cover page of each Reporting Person.

         
        As of the date hereof, Hunt Holdings LP directly owns 829,280 shares of common stock, par value $0.001 per share (“Common Stock”) of the Issuer.  Woody L. Hunt is the majority shareholder of Hunt Guaranty, which is the sole member of HuntVest, which is the general partner of Hunt Holdings LP. As a result, Mr. Hunt and each of the foregoing entities may be deemed to have an indirect beneficial ownership of the shares directly beneficially owned by Hunt Holdings LP. 
           
        Pursuant to Rule 13d-4 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Reporting Persons declare that filing this Schedule 13G shall not be construed as an admission that any such person is, for the purposes of Section 13(d) and/or Section 13(g) of the Exchange Act, the beneficial owner of any Common Stock covered by this Schedule 13G except to the extent of such person’s direct ownership of such Common Stock, and except to the extent of such direct ownership, such beneficial ownership is expressly disclaimed by each Reporting Person. 
           
      (b) Percent of class:
           
       

    The calculation of beneficial ownership percentage is based on 17,637,278 shares of Common Stock outstanding as of November 8, 2024, as reported by the Issuer in its Form 10-Q filed with the Securities and Exchange Commission for the quarter ended September 30, 2024.

           
    (c) Name of Person Filing:
           
        (i) Sole power to vote or to direct the vote:
           
          See row 5 of the cover page of each Reporting Person.
           
        (ii) Shared power to vote or to direct the vote:
           
          See row 6 of the cover page of each Reporting Person.
           
        (iii) Sole power to dispose or to direct the disposition of:
           
          See row 7 of the cover page of each Reporting Person.
           
        (iv) Shared power to dispose or to direct the disposition of:
           
          See row 8 of the cover page of each Reporting Person.

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 8 of 9

     

     

    ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. ☒
       
    ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON.
       
      Not applicable.
       
    ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY.
       
      Not applicable.
       
    ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP.
       
      Not applicable.
       
    ITEM 9. NOTICE OF DISSOLUTION OF GROUP.
     

     

      Not applicable.
       
    ITEM 10. CERTIFICATION.
       
      Not applicable.

     

    Exhibit Index

     

    Exhibit 99.1 Joint Filing Agreement, dated as of February 7, 2020, among Hunt Holdings Limited Partnership, HuntVest, LLC, Hunt Guaranty, Inc. and Woody L. Hunt. (Previously filed.)

     

     

     

     

     

    CUSIP No. 30068X103 SCHEDULE 13G Page 9 of 9

      

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. 

    Dated:  December 12, 2024

     

      HUNT HOLDINGS LIMITED PARTNERSHIP  
         
      By: HuntVest, LLC, its general partner  
      By: Hunt Guaranty, Inc., its sole member  
           
      By: /s/ Matthew D. Hunt  
        Name: Matthew D. Hunt  
        Title: Managing Partner  
           
      HUNTVEST, LLC  
           
      By: Hunt Guaranty, Inc., its sole member  
           
      By: /s/ Matthew D. Hunt  
        Name: Matthew D. Hunt  
        Title: Managing Partner  
           
      HUNT GUARANTY, INC.  
           
           
      By: /s/ Matthew D. Hunt  
        Name: Matthew D. Hunt  
        Title: Managing Partner  
           

      /s/ Paul D. Donnelly  
      Paul D. Donnelly, attorney-in-fact for Woody L. Hunt  

     

     

    Get the next $XGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $XGN

    DatePrice TargetRatingAnalyst
    8/5/2022Overweight → Sector Weight
    KeyBanc Capital Markets
    11/11/2021$33.00 → $30.00Overweight
    Keybanc
    10/15/2021$26.00Outperform
    Cowen
    More analyst ratings

    $XGN
    SEC Filings

    See more
    • SEC Form S-3 filed by Exagen Inc.

      S-3 - EXAGEN INC. (0001274737) (Filer)

      6/20/25 4:21:58 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - EXAGEN INC. (0001274737) (Filer)

      6/11/25 4:49:20 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form S-8 filed by Exagen Inc.

      S-8 - EXAGEN INC. (0001274737) (Filer)

      5/20/25 4:43:58 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

      CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

      6/23/25 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Closing of $20.2 Million Public Offering Including Full Exercise of Underwriter's Option to Purchase Additional Shares

      CARLSBAD, Calif., May 09, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced that it has completed the sale of an additional 502,500 shares of its common stock at a public offering price of $5.25 per share on May 8, 2025, pursuant to the full exercise of the option granted by Exagen to the underwriter in connection with its previously announced public offering of 3,350,000 shares of common stock, which closed on May 9, 2025. All of the shares in the public offering, including the full exercise of the underwriter's option, were sold by Exagen, with gross proceeds to Exagen of approximately $20.2 million, before deducting u

      5/9/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Prices Public Offering of Common Stock

      CARLSBAD, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced the pricing of its previously announced underwritten public offering of 3,350,000 shares of its common stock at a public offering price of $5.25 per share. All of the shares in the offering will be sold by Exagen, with gross proceeds to Exagen expected to be $17,587,500 before deducting underwriting discounts and commissions and offering expenses. Exagen has granted the underwriters a 30-day option to purchase up to an additional 502,500 shares on the same terms and conditions. The offering is expected to close on May 9, 2025, subject to the satis

      5/8/25 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Black Jeffrey G. bought $66,448 worth of shares (22,298 units at $2.98), increasing direct ownership by 9% to 274,492 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/19/24 7:24:38 PM ET
      $XGN
      Medical Specialities
      Health Care
    • President and CEO Aballi John bought $68,297 worth of shares (24,305 units at $2.81), increasing direct ownership by 4% to 689,799 units (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      11/18/24 6:32:33 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Aballi John bought $77,570 worth of shares (40,401 units at $1.92) (SEC Form 4)

      4 - EXAGEN INC. (0001274737) (Issuer)

      5/16/24 8:02:50 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Exagen downgraded by KeyBanc Capital Markets

      KeyBanc Capital Markets downgraded Exagen from Overweight to Sector Weight

      8/5/22 9:00:50 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Keybanc reiterated coverage on Exagen with a new price target

      Keybanc reiterated coverage of Exagen with a rating of Overweight and set a new price target of $30.00 from $33.00 previously

      11/11/21 4:33:21 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Cowen resumed coverage on Exagen with a new price target

      Cowen resumed coverage of Exagen with a rating of Outperform and set a new price target of $26.00

      10/15/21 7:34:02 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form 4 filed by Director Kim Paul

      4/A - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 8:32:07 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Stokes Frank

      4 - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 6:49:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form 4 filed by Director Kim Paul

      4 - EXAGEN INC. (0001274737) (Issuer)

      6/12/25 5:57:17 PM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Michael Mahler, PhD Joins Exagen as Chief Scientific Officer to Enhance Leadership in Autoimmune Diagnostics

      CARLSBAD, Calif., June 23, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of innovative autoimmune testing, is pleased to announce the appointment of Dr. Michael Mahler as Chief Scientific Officer. With an extensive background in immunology and autoimmune research, Dr. Mahler brings a wealth of expertise to Exagen's mission of improving the diagnosis and treatment of autoimmune diseases. Dr. Mahler received his Ph.D. from the Institute of Molecular Genetics at the University of Heidelberg, Germany. During his doctoral research, he worked at the Scripps Research Institute, more specifically in the lab of Prof. Eng Tan and Michael Pollard, pioneers in autoimmune resea

      6/23/25 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Appoints Jeffrey G. Black as New Chief Financial Officer

      CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions announced today the appointment of Jeffrey G. Black, to the role of Chief Financial Officer (CFO), effective September 1, 2024. Mr. Black replaces Kamal Adawi, who will be stepping down, and John Aballi will act as interim CFO through the end of August. "I sincerely thank Kamal for his leadership and numerous contributions to Exagen over the past decade," said John Aballi, President and CEO of Exagen. "Kamal has been extremely supportive throughout my time with the Company, and I am very appreciative of his dedication to our customers and organization. I appreci

      8/1/24 9:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Announces Changes to the Board of Directors

      CARLSBAD, Calif., April 26, 2024 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today announced changes to the Board of Directors. Exagen is pleased to announce Scott Kahn, Ph.D. is joining the Board as a Class I Director. Dr. Kahn has a distinguished career in life sciences spending over 30 years in global leadership positions. Prior to starting his career in the life science industry, he was an assistant professor of organic chemistry at the University of Illinois. He spent over 10 years at the scientific software company, Accelrys, where he held several positions with increasing responsibility including SVP, General Manager and Chief

      4/26/24 8:30:00 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Exagen Inc.

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      12/12/24 5:00:54 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 2:42:55 PM ET
      $XGN
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Exagen Inc. (Amendment)

      SC 13G/A - EXAGEN INC. (0001274737) (Subject)

      2/14/24 7:12:55 AM ET
      $XGN
      Medical Specialities
      Health Care

    $XGN
    Financials

    Live finance-specific insights

    See more
    • Exagen Inc. Reports Record Q1 2025 Revenue Driven by Growth in Average Selling Price and Testing Volume

      CARLSBAD, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March 31, 2025, and recent corporate updates.   Three Months Ended March 31,   2025   2024 (in thousands, except ASP data)  Revenue $15,498  $14,415 Gross margin  58.9%  59.6%Operating expenses $12,488  $11,601 Operating loss $(3,365) $(3,003)Net loss $(3,752) $(3,360)Adjusted EBITDA $(2,508) $(1,992)Cash and cash equivalents $11,194  $27,267 Trailing-twelve-month average selling price (ASP) $419  $377           Q1 2025 Highlights and Recent Corporate Updates: Delivered record total revenue of $15.5 million

      5/5/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. to Announce First Quarter 2025 Financial Results on May 5, 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, will release financial results for the quarter ended March 31, 2025, before the market opens on Monday, May 5, 2025. John Aballi, Exagen's President and Chief Executive Officer, and Jeff Black, Chief Financial Officer, will host a conference call to review the company's results at 8:30 a.m. ET (5:30 a.m. PT). Interested parties may access the conference call by dialing 201-389-0918 (U.S.) or +1-877-407-0890 (international). Participants wishing to access the call via webcast should use the link posted on the Exagen investor relations website at investors.exagen.com.

      4/21/25 4:05:00 PM ET
      $XGN
      Medical Specialities
      Health Care
    • Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2024 Results and Business Highlights

      Delivered record full-year total revenue and AVISE CTD average selling priceImproved full-year adjusted EBITDA loss and cash use by over 40%Commercialized new biomarkers to enhance clinical utility of AVISE CTD CARLSBAD, Calif., March 11, 2025 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ:XGN), a leading provider of autoimmune testing, today reported financial results for the fourth quarter and full year ended December 31, 2024, and recent business highlights.   Three Months Ended December 31, Year Ended December 31,   2024   2024 (in thousands, except ASP data)  Revenue $13,655  $55,641 Gross margin  62.1%  59.5%Operating expenses $11,860  $46,748 Loss from operations $(3,383) $(13,636)Net los

      3/11/25 8:00:00 AM ET
      $XGN
      Medical Specialities
      Health Care